Differences in skeletal muscle loss caused by cytotoxic chemotherapy and molecular targeted therapy in patients with advanced non‐small cell lung cancer

Publisher： John Wiley & Sons Inc

E-ISSN： 1759-7714|9|1|99-104

ISSN： 1759-7706

Source： Thoracic Cancer, Vol.9, Iss.1, 2018-01, pp. : 99-104

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Efficacy and safety of chemotherapy for newly diagnosed advanced non‐small cell lung cancer with venous thromboembolism

By  

Thoracic Cancer, Vol. 6, Iss. 6, 2015-11 ,pp. : 772-777

John Wiley & Sons Inc

Access to resources Recommend Favorite

Heterogeneous prognosis and adjuvant chemotherapy in pathological stage I non‐small cell lung cancer patients

By  

Thoracic Cancer, Vol. 6, Iss. 5, 2015-09 ,pp. : 620-628

John Wiley & Sons Inc

Access to resources Recommend Favorite

Platelet‐to‐lymphocyte ratio predicts the prognosis of patients with non‐small cell lung cancer treated with surgery and postoperative adjuvant chemotherapy

By  

Thoracic Cancer, Vol. 9, Iss. 1, 2018-01 ,pp. : 112-119

John Wiley & Sons Inc

Access to resources Recommend Favorite

Self‐reported depression among patients with non‐small cell lung cancer

By  

Thoracic Cancer, Vol. 6, Iss. 3, 2015-05 ,pp. : 334-337

John Wiley & Sons Inc

Access to resources Recommend Favorite

Survival analysis of patients with advanced non‐small cell lung cancer receiving tyrosine kinase inhibitor (TKI) treatment: A multi‐center retrospective study

By  

Thoracic Cancer, Vol. 9, Iss. 2, 2018-02 ,pp. : 278-283

John Wiley & Sons Inc

Access to resources Recommend Favorite